Loading...
•
Dec 31, 2025
Danaher Q4 2025 Earnings Report
Danaher posted a solid Q4 performance with strong EPS growth and gains in core revenue.
Key Takeaways
Danaher delivered strong Q4 2025 results, with adjusted EPS rising to $2.23 and revenue hitting $6.8 billion. Net income came in at $1.2 billion, driven by strength in its Bioprocessing, Diagnostics, and Life Sciences businesses.
Adjusted EPS grew to $2.23 in Q4 2025.
Revenue reached $6.8 billion, a 4.5% increase YoY.
Biotechnology segment led growth with 9.0% YoY revenue increase.
Free cash flow reached $1.77 billion for the quarter.
Revenue by Segment
Forward Guidance
Danaher expects low single-digit core revenue growth in Q1 2026 and 3%–6% growth for full-year 2026, supported by continued strength in Biotech and Diagnostics.
Positive Outlook
- Core revenue expected to grow 3%–6% in FY26.
- Q1 2026 core revenue growth anticipated in the low single-digit range.
- Biotech segment forecasted to grow at a high single-digit rate in Q1 2026.
- Adjusted EPS guidance for FY26 is $8.35–$8.50.
- Diagnostics expected to return to low single-digit growth in FY26.
Challenges Ahead
- Life Sciences expected to remain flat or slightly decline in Q1 2026.
- Diagnostics projected to decline slightly in Q1 2026.
- Core operating margin in Diagnostics declined YoY in Q4.
- Currency exchange rates impacted Q4 reported revenue negatively by 2.5%.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...